Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, February 25 at ...

An Ionis Pharmaceuticals drug has preliminary data showing it met the main goal of its pivotal test in a rare disease with only a handful of approved treatments. With these results in hand, Ionis is ...

– Positive topline results announced for pivotal Phase 3 program of bepirovirsen in chronic hepatitis B; first of five Phase 3 readouts from partnered programs expected this year – CARLSBAD, Calif., ...

On Tuesday, Ionis Pharmaceuticals Inc (NASDAQ:IONS) and Ono Pharmaceutical Co., Ltd entered into a license agreement in which Ono obtains exclusive global rights for the development and ...

Ionis has several revenue-generating therapies and two with pending PDUFA dates. Its phase 3 pipeline boasts five molecules with a sixth expected soon. An alluring business model is falling short for ...

Ionis PharmaceuticalsIONS guided to north of $5 billion in peak sales for its current programs on Tuesday. Early Wednesday, Ionis stock hit a six-year high after snagging a price-target hike. The ...

Ionis Pharmaceuticals' Q4 earnings beat expectations, but guidance for 2025 was slightly below consensus, leading to a HOLD rating pending further catalysts. TRYNGOLZA's approval for FCS is promising, ...

Healthcare: Policy Headwinds Continue to Weigh on Stocks, but Valuations Remain Attractive ...

A genetic medicine from Ionis Pharmaceuticals designed to reduce high levels of cholesterol has achieved the main goal of a Phase 2 study, but the results are short of what partner AstraZeneca hoped ...

Carlsbad-based pharmaceutical company Ionis announced Wednesday that it has established a $25,000 scholarship to provide remote classes and therapy for San Diego-area ALS patients amid social ...

We’re maintaining our $62 fair value estimate for Ionis IONS following in line second-quarter results, and more importantly, indications that the firm’s late-stage pipeline remains on track. Steady ...